December 14, 2009 08:30 ET
Market Pulse Breaking News Alert for Monday, December 14, 2009: RMCP - RevMed Launches RevVac Safety Syringe Mass Manufacturing Process and Revenue on Target to Hit $14.8 Million in 2010!
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse
ATLANTA, GA--(Marketwire - December 14, 2009) - Market Pulse News Alert for this AM, Stocks to
Watch are: Revolutions Medical Corporation (OTCBB: RMCP), Sunesis
Pharmaceuticals Inc. (NASDAQ: SNSS), Blue Gem Enterprise (OTCBB: BGEM)
and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC).
Investors need to be watching Revolutions Medical Corporation (OTCBB: RMCP)
this AM! Revolutions Medical Corporation (RevMed) is engaged in the design,
development, commercialization and acquisition of new products and tools to
make healthcare safer and less expensive. RevMed's products include
safety-engineered medical devices (SEMDs) and the flagship RevVac safety
syringe (FDA Approved), safety blood drawing devices, and safety IV
catheters. The products use a proprietary patented technology in which a
vacuum causes the needle to retract into the barrel of the syringe or
device after an injection is administered or blood is drawn. RevMed owns
the patents to manufacture the disposable retractable syringe and
phlebotomy device. The world market for SEMDs is projected to exceed $2
billion this year and is forecasted to maintain a 20% annual growth rate in
the near term. RevMed also offers RevColor, RevDisplay and Rev3D software
solutions and proprietary tools that are compatible with standard MRIs and
standard PACS. The software includes sorting of images, color, 3D, and
automatic segmentation of images. These tools will enhance the physician's
diagnostic confidence in an industry that is growing at 10% - 15% (more
than 25 million procedures) per year with a worldwide market potential for
these tools that exceeds $3.5 billion. The company is continually looking
for new and improved technology through internal product development and
acquisition. The company's future growth will be powered by new product
line introductions, and the material expansion of existing successful
lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally
invasive) image-based localization technology, is one of those product
lines pursuing the $9.5 billion breast screening industry. RevMed's Breast
Biopsy System, the MRI enhancement software and the SEMDs will be launching
in the next 18 months. All three markets are immediately addressable and
total more than $14 billion. RevMed recently introduced its proprietary
suite of MRI software products at the Radiology Society of North America
annual meeting with great success. Radiologists and universities world-wide
received presentations at the RMCP booth. A number of these contacts could
play an important role in the company's ongoing efforts to clinically
validate specific applications of its MRI tools prior to the 2010
commercial launch. Never has health care been a hotter issue, and the focus
of the conversation is on increased safety at dramatically reduced cost.
Revolutions Medical has the formula for success, and one that has them
immediately positioned for a high growth future. With 3 recurring revenue
business lines with blended gross margins projected to exceed 50% and
anticipated profitability in its first full year of operations, Revolutions
Medical Corporation is poised to become a significant player in the
healthcare and medical devices industry! RMCP has had several excellent
press releases out lately and one again before today's opening bell
announcing that it has initiated the mass manufacturing process for the
RevVac safety syringe, which is already FDA approved! The company also said
it's on pace to meet its Q2 '10 sales launch goal and $14.8 million 2010
revenue projection! This could be great news for investors!
Revolutions Medical Corporation (OTCBB: RMCP), producers of the RevVac
safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today
announced that it has initiated the mass manufacturing process for the
RevVac safety syringe, which is already FDA approved. By hitting its
primary milestone, RevMed satisfies its previously announced commitment to
begin production in Q4 '09. It also stays on pace to meet its Q2 '10 sales
launch goal and $14.8 million 2010 revenue projection.
"After years in developing what we believe is the world's best safety
syringe, we are extremely pleased to announce that the plan is now reality
-- we have launched the mass manufacturing process for the RevVac safety
syringe," stated Revolutions Medical CTO Richard Theriault. "This
constitutes the next step toward full scale high volume production and
commercialization. With this first phase we will 1) provide market-ready
samples and 2) complete the steps necessary to ensure ultimate delivery of
a high quality, high volume manufacturing solution. We have been working
closely with the team at Goddard Technologies (www.goddardtech.com) -- the
group responsible for the recent crucial product refinements -- towards
this, our primary pre-sales milestone. We remain precisely on pace with our
stated goals, and we can now demonstrate tangible progress toward bringing
the much-anticipated RevVac to market in Q2 '10."
Andrew Goddard, President of Goddard Technologies, stated, "We are pleased
to be working with Revolutions Medical on the first phase of the RevVac
Safety Syringe mass manufacturing process. The RevVac design is unique and
elegant as an easy to use, single handed vacuum safety syringe. That we
could contribute to a product of such high caliber is a source of great
pride for Goddard Technologies."
About Revolutions Medical Corporation (www.revolutionsmedical.com)
RevMed's products include the RevVac safety syringe (FDA approved), safety
blood drawing device and safety IV catheter. RevMed also provides RevColor,
RevDisplay and Rev3D -- software solutions and proprietary tools that are
compatible with standard MRIs and standard PACS. The software suite's
functionality includes sorting of images, color, 3D and automatic
segmentation of images.
Stocks in the news, and acting well as of late, include: Sunesis
Pharmaceuticals Inc. (NASDAQ: SNSS), Blue Gem Enterprise (OTCBB: BGEM)
and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC).
Information contained herein is the opinion of Market-Pulse.com ("MP") and
is intended to be used strictly for informational purposes. You should be
aware that MP attempts to assure itself of the accuracy of the information
contained in the analyses it publishes. In this regard, MP does, at times,
rely on the accuracy of information supplied to it by the companies which
are the subject of MP's analyses and/or parties related to those companies.
MP also relies on the accuracy and integrity of information that is
contained in company press releases and reports filed with the SEC. The
companies mentioned in this publication have not approved the content or
timing of the information being published unless otherwise noted.
MP, because it relies on information supplied by various third parties
disclaims any responsibility for the accuracy of such information. Any
investor considering making an investment in any security which has been
the subject of a MP analysis or opinion should, before making any such
investment, consult with his/her market professional and/or do his/her own
independent research regarding the company which is the subject of an MP
opinion, recommendation or analysis. Information regarding companies which
MP has opined upon is normally available from many sources including the
subject company's filings with the SEC and various press releases issued by
the company.
You should be aware that MP is often compensated for issuing analyses,
recommendations or opinions concerning particular companies. Its opinion is
therefore not unbiased and you should consider this factor when evaluating
MP's statements regarding a company. MP has been compensated twenty five
thousand restricted shares of Revolutions Medical Corporation by the
company. MP's officers and directors reserve the right to buy
additional shares of the companies discussed in this opinion and may profit
in the event those shares rise in value. When MP receives shares as
compensation for a profiled company, MP may sell part or all of any such
shares during the period in which MP is performing such services.
Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market
Pulse LLC.